Latest news articles

Added 13 hours ago Drug news

Interim analysis of Phase III OLYMPUS trial of MitoGel shows positive results in urothelial cancer.- UroGen Pharma.

UroGen Pharma announced new findings from an interim analysis of the ongoing pivotal Phase III OLYMPUS clinical trial of UGN-101...

Added 1 day ago Drug news

EU approves Cabometyx to treat intermediate- or poor- risk advanced renal cell carcinoma.- Ipsen + Exelixis Inc.

Ipsen has announced that the European Commission (EC) has approved Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment...

Added 3 days ago Drug news

Phase III SPARTAN study of Erleada shows reduced risk of prostate cancer.- Janssen Pharma.

Janssen Pharmaceutical presented a post-hoc analysis from the Phase III SPARTAN study that showed treatment with Erleada (apalutamide) significantly reduced...

Search all news articles for Oncology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

What's on the horizon?

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Guidelines

Guidelines on Penile Cancer

The European Association of Urology (EAU) Guidelines on Penile Cancer provides up-to-date information on the diagnosis and management of penile squamous cell carcinoma (SCC).

Added 4 years ago

Guidelines on Primary Urethral Carcinoma

The European Association of Urology (EAU) Guidelines Group on Muscle-invasive and Metastatic Bladder Cancer has prepared these guidelines to deliver current evidence-based information on the diagnosis and treatment of patients with...

Added 3 years ago

EAU Guidelines on Prostate Cancer

The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals assess the evidence-based management of prostate cancer (PCa).

Added 2 years ago

Search all guidelines for Oncology
 

Journal articles

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.

Introduction: Anaplastic lymphoma kinase (ALK) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes.

Added 1 day ago

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Purpose: Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia...

Added 1 day ago

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.

B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown.

Added 1 day ago

Search all journal articles for Oncology
 

Clinical trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 6 months ago

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation (COLLISION)

The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.

Added 6 months ago

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study (ERASG1)

This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.

Added 6 months ago

Search all clinical trials for Oncology
 

Blog Posts

Alex Keen

ELCC 2018 ‒ Roundup of this year’s conference

Posted 1 month ago

At the recent ELCC, held from 11‒14 April 2018, several hundred abstracts were presented detailing the latest cutting-edge research in lung cancer treatment and care. Brief summaries of some of the key abstracts are found here.

Alex Keen

ELCC 2018 ‒ And the Heine H. Hansen Award goes to…

Posted 1 month ago

Discover this year's Heine H. Hansen award winner, given to a scientific investigator who has made special, wide-reaching and significant contributions to lung cancer research and education, recognising their lifelong achievements.

Alex Keen

EBCC 2018 – Roundup of this year's conference

Posted 1 month ago

At the recent European Breast Cancer Conference the best and brightest in breast cancer research and care met to present and discuss the latest breakthroughs. Brief summaries of some of the key abstracts are found here.

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Managing patients at risk of prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Oncology